Transformación Celular Neoplásica/genética; Metilación de ADN; Epigénesis Genética; Proteínas de Neoplasias/genética; Neoplasias Gástricas/genética; Transformación Celular Neoplásica/patología; Islas de CpG; Histonas/genética; Histonas/metabolismo; Humanos; MicroARNs/genética; MicroARNs/metabolismo; Proteínas de Neoplasias/metabolismo; Nucleosomas/genética; Nucleosomas/metabolismo; Regiones Promotoras Genéticas; Proto-Oncogenes Mas; ARN no Traducido/genética; ARN no Traducido/metabolismo; Transducción de Señal; Neoplasias Gástricas/patología; Proteínas Supresoras de Tumor/antagonistas & inhibidores; Proteínas Supresoras de Tumor/genética; Proteínas Supresoras de Tumor/metabolismo

5-hmC; 5-hydroxymethylcytosine; 5-mC; 5-methylcytosine; ADAM metallopeptidase domain 23; ADAM metallopeptidase with thrombospondin type 1 motif, 9; ADAM23; ADAMTS9; AML; APC; ARID1A; AT motif-binding factor 1; AT rich interactive domain 1A (SWI-like); ATBF1; Acute myelocytic leukemia; Adenomatosis polyposis coli; B-cell translocation gene 4; BCL2/adenovirus E1B 19kDa interacting protein 3; BMP-2; BNIP3; BS; BTG4; Biomarkers; Bisulfite sequencing; Bone morphogenetic protein 2; C-MET; CACNA1G; CACNA2D3; CD44; CD44 molecule (Indian blood group); CDH1; CDK4; CDK6; CDKN1C; CDKN2A; CDX2; CGI; CHD5; CHFR; CKLF-like MARVEL transmembrane domain containing 3; CMTM3; CNS; CRBP1; Cadherin 1 or E-cadherin; Calcium channel, voltage-dependent, T type, alpha 1G subunit; Calcium channel, voltage-dependent, alpha 2/delta subunit 3; Caudal type homeobox 2; Central nervous system; Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase; Chromodomain helicase DNA binding protein 5; Chromosome 2 open reading frame 40; Clinical outcomes; CpG islands; Cyclin-dependent kinase 4; Cyclin-dependent kinase 6; Cyclin-dependent kinase inhibitor 1A; Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor 1C; Cyclin-dependent kinase inhibitor 2A; Cyclin-dependent kinase inhibitor 2B; DAB2 interacting protein; DACT1; DAPK; DNA; DNA methylatransferases; DNA mismatch repair; DNMT; Dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis); Death-associated protein kinase; Deoxyribose Nucleic Acid; Dickkopf 3 homolog (Xenopus laevis); Dkk-3; EBV; ECRG4; EDNRB; EGCG; ERBB4; Endothelin receptor type B; Epigallocatechin gallate; Epigenetics; Epstein­Barr Virus; FDA; FLNc; Filamin C; Food and Drug Administration; GC; GDNF; GI endoscopy; GPX3; GRIK2; GSTP1; Gastric cancer; Gene methylation; Glutamate receptor, ionotropic, kainate 2; Glutathione S-transferase pi 1; Glutathione peroxidase 3 (plasma); H. pylori; HACE1; HAI-2/SPINT2; HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1; HGFA; HLTF; HOXA1; HOXA10; HRAS-like suppressor; HRASLS; Helicase-like transcription factor; Helicobacter pylori; Homeobox A1; Homeobox A10; Homeobox D10; HoxD10; IGF-1; IGF-1R; IGFBP3; IL-1ß; ITGA4; Insulin-like growth factor 1 (somatomedin C); Insulin-like growth factor I receptor; Insulin-like growth factor binding protein 3; Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor); Interleukin 1, beta; KL; KRAS; Klotho; LL3; LMP2A; LOX; LRP1B; Low density lipoprotein receptor-related protein 1B; Lysyl oxidase; MAPK; MBPs; MDS; MGMT; MINT25; MLF1; MLL; MMR; MSI; MSP; Matrix metallopeptidase 24 (membrane-inserted); Met proto-oncogene (hepatocyte growth factor receptor); Methyl-CpG binding proteins; Methylation-specific PCR; Microsatellite instability; Myeloid leukemia factor 1; Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); Myeloid/lymphoid or mixed-lineage leukemia 3; NDRG family member 2; NDRG2; NPR1; NR3C1; Natriuretic peptide receptor A/guanylate cyclase A; Notch 1; Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor); O-6-methylguanine-DNA methyltransferase; PCDH10; PCDH17; PI3K/Akt; PIK3CA; PR domain containing 5; PRDM5; PTCH1; Patched 1; Phosphatidylethanolamine binding protein 1; Protein tyrosine phosphatase, non-receptor type 6; Protocadherin 10; Protocadherin 17; Q-MSP; Quantitative methylation-specific PCR; RAR-related orphan receptor A; RARRES1; RARß; RAS/RAF/MEK/ERK; RASSF1A; RASSF2; RBP1; RKIP; RORA; ROS; RUNX3; Ras association (RalGDS/AF-6) domain family member 1; Ras association (RalGDS/AF-6) domain family member 2; Rb; Retinoic acid receptor responder (tazarotene induced) 1; Retinoic acid receptor, beta; Retinol binding protein 1, cellular; Runt-related transcription factor 3; S-adenosylmethionine; SAM; SFRP2; SFRP5; SHP1; SOCS-1; STAT3; SYK; Secreted frizzled-related protein 2; Secreted frizzled-related protein 5; Serine peptidase inhibitor, Kunitz type, 2; Spleen tyrosine kinase; Suppressor of cytokine signaling 1; TCF4; TET; TFPI2; TGF-ß; TIMP metallopeptidase inhibitor 3; TIMP3; TNM; TP73; TSP1; Thrombospondin 1; Tissue factor pathway inhibitor 2; Transcription factor 4; Tumor Node Metastasis; Tumor protein p73; V-erb-a erythroblastic leukemia viral oncogene homolog 4; ZFP82 zinc finger protein; ZIC1; ZNF545; Zinc finger protein of the cerebellum 1; gastrointestinal endoscopy; glial cell derived neurotrophic factor; hDAB2IP; hMLH1; hepatocyte growth factor activator; latent membrane protein; mutL homolog 1; myelodysplastic syndromes; p15; p16; p21; p27; p53; p73; phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; phosphoinositide 3-kinase (PI3K)/Akt; reactive oxygen species; retinoblastoma; signal transducer and activator of transcription-3; ten-eleven translocation; transforming growth factor-ß; tumor protein p53; tumor protein p73; v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog